Elite Pharmaceuticals annual net profit margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Elite Pharmaceuticals Net Profit Margin Growth & History (ELTP)
Elite Pharmaceuticals's net profit margin was 30.14% for fiscal 2026.
View full Elite Pharmaceuticals company overviewElite Pharmaceuticals annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-03-31 | 30.14% | +35.28 pp |
| 2025 | 2025-03-31 | −5.13% | −40.65 pp |
| 2024 | 2024-03-31 | 35.51% | +25.08 pp |
| 2023 | 2023-03-31 | 10.43% | −17.15 pp |
| 2022 | 2022-03-31 | 27.58% | +7.53 pp |
| 2021 | 2021-03-31 | 20.05% | +32.50 pp |
| 2020 | 2020-03-31 | −12.45% | +110.15 pp |
| 2019 | 2019-03-31 | −122.60% | −73.36 pp |
| 2018 | 2018-03-31 | −49.25% | −88.79 pp |
| 2017 | 2017-03-31 | 39.54% | +45.01 pp |
| 2016 | 2016-03-31 | −5.46% | −109.56 pp |
| 2015 | 2015-03-31 | 104.09% | +1000.80 pp |
| 2014 | 2014-03-31 | −896.71% | −940.43 pp |
| 2013 | 2013-03-31 | 43.72% | +664.90 pp |
| 2012 | 2012-03-31 | −621.19% | −302.80 pp |
| 2011 | 2011-03-31 | −318.38% | — |
Elite Pharmaceuticals quarterly net profit margin
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q1 2027 | 2026-06-30 | 18.27% | +32.90 pp |
| Q4 2026 | 2026-03-31 | 45.31% | −7.82 pp |
| Q3 2026 | 2025-12-31 | 58.86% | +134.69 pp |
| Q2 2026 | 2025-09-30 | 37.73% | +96.18 pp |
| Q1 2026 | 2025-06-30 | −14.63% | −17.91 pp |
| Q4 2025 | 2025-03-31 | 53.12% | +34.59 pp |
| Q3 2025 | 2024-12-31 | −75.83% | −80.37 pp |
| Q2 2025 | 2024-09-30 | −58.45% | −163.94 pp |
| Q1 2025 | 2024-06-30 | 3.27% | −9.44 pp |
| Q4 2024 | 2024-03-31 | 18.53% | +32.75 pp |
| Q3 2024 | 2023-12-31 | 4.55% | −27.56 pp |
| Q2 2024 | 2023-09-30 | 105.49% | +87.84 pp |
| Q1 2024 | 2023-06-30 | 12.71% | +8.73 pp |
| Q4 2023 | 2023-03-31 | −14.22% | −45.87 pp |
| Q3 2023 | 2022-12-31 | 32.11% | +6.67 pp |
| Q2 2023 | 2022-09-30 | 17.65% | −3.35 pp |
| Q1 2023 | 2022-06-30 | 3.99% | −29.87 pp |
| Q4 2022 | 2022-03-31 | 31.66% | +42.64 pp |
| Q3 2022 | 2021-12-31 | 25.44% | −7.83 pp |
| Q2 2022 | 2021-09-30 | 21.00% | −12.54 pp |
| Q1 2022 | 2021-06-30 | 33.86% | +19.56 pp |
| Q4 2021 | 2021-03-31 | −10.98% | −29.91 pp |
| Q3 2021 | 2020-12-31 | 33.28% | +70.09 pp |
| Q2 2021 | 2020-09-30 | 33.54% | +67.96 pp |
| Q1 2021 | 2020-06-30 | 14.29% | +5.96 pp |
| Q4 2020 | 2020-03-31 | 18.93% | +217.16 pp |
| Q3 2020 | 2019-12-31 | −36.81% | +50.21 pp |
| Q2 2020 | 2019-09-30 | −34.43% | +155.11 pp |
| Q1 2020 | 2019-06-30 | 8.33% | +86.19 pp |
| Q4 2019 | 2019-03-31 | −198.22% | −21.08 pp |
| Q3 2019 | 2018-12-31 | −87.02% | −67.70 pp |
| Q2 2019 | 2018-09-30 | −189.54% | −301.33 pp |
| Q1 2019 | 2018-06-30 | −77.86% | +49.51 pp |
| Q4 2018 | 2018-03-31 | −177.14% | +58.86 pp |
| Q3 2018 | 2017-12-31 | −19.33% | −90.84 pp |
| Q2 2018 | 2017-09-30 | 111.79% | −45.99 pp |
| Q1 2018 | 2017-06-30 | −127.37% | −160.96 pp |
| Q4 2017 | 2017-03-31 | −236.00% | −399.60 pp |
| Q3 2017 | 2016-12-31 | 71.51% | +629.08 pp |
| Q2 2017 | 2016-09-30 | 157.78% | +214.82 pp |
| Q1 2017 | 2016-06-30 | 33.60% | −185.17 pp |
| Q4 2016 | 2016-03-31 | 163.60% | +678.19 pp |
| Q3 2016 | 2015-12-31 | −557.57% | −1101.73 pp |
| Q2 2016 | 2015-09-30 | −57.04% | −554.49 pp |
| Q1 2016 | 2015-06-30 | 218.77% | +398.98 pp |
| Q4 2015 | 2015-03-31 | −514.59% | +7928.80 pp |
| Q3 2015 | 2014-12-31 | 544.17% | +606.90 pp |
| Q2 2015 | 2014-09-30 | 497.45% | +1329.03 pp |
| Q1 2015 | 2014-06-30 | −180.21% | −307.91 pp |
| Q4 2014 | 2014-03-31 | −8,443.39% | −8548.26 pp |
| Q3 2014 | 2013-12-31 | −62.73% | −1465.07 pp |
| Q2 2014 | 2013-09-30 | −831.58% | −997.04 pp |
| Q1 2014 | 2013-06-30 | 127.70% | +1946.38 pp |
| Q4 2013 | 2013-03-31 | 104.87% | +1182.47 pp |
| Q3 2013 | 2012-12-31 | 1,402.34% | −315.71 pp |
| Q2 2013 | 2012-09-30 | 165.47% | −4912.13 pp |
| Q1 2013 | 2012-06-30 | −1,818.68% | +1285.78 pp |
| Q4 2012 | 2012-03-31 | −1,077.60% | +291.23 pp |
| Q3 2012 | 2011-12-31 | 1,718.05% | +1234.63 pp |
| Q2 2012 | 2011-09-30 | 5,077.60% | +4890.17 pp |
| Q1 2012 | 2011-06-30 | −3,104.46% | −2531.16 pp |
| Q4 2011 | 2011-03-31 | −1,368.82% | — |
| Q3 2011 | 2010-12-31 | 483.42% | — |
| Q2 2011 | 2010-09-30 | 187.43% | — |
| Q1 2011 | 2010-06-30 | −573.30% | — |
Elite Pharmaceuticals net profit margin trends
Over the last five fiscal years, Elite Pharmaceuticals's net profit margin increased from 20.05% to 30.14%, a change of +10.09 percentage points. The latest reported quarter, Q1 2027, shows 18.27%.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Elite Pharmaceuticals source filings ↗